Re‐Evaluation of Fixed Dosing Versus Body Size‐Based Dosing Approaches for Large Molecule Therapeutics in Adults
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.70015 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Andrew B SyBing und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Oncology, San Diego, California, USA. Hauptthemen laut MEDLINE: Body Size, Drug Dosage Calculations. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Wang et al . 1 (2009) and Zhang et al . 2 (2011) recommended a fixed dosing approach for large molecule therapeutics for first‐in‐human (FIH) trials, based on the finding that the majority of α values (body size effect on clearance) were < 0.5 across 12 monoclonal antibodies (mAbs) and 18 therapeutic proteins (TPs) and peptides, and fixed dosing provides advantages such as convenience, reduced medical errors, and cost‐effectiveness. They also recommended that the approved dosing approach should be determined by α and the therapeutic window. This review aims to re‐evaluate these recommendations using a larger dataset ( N = 143) of diverse molecules. Results showed 62% (78/126) of non‐ADC drugs were approved with fixed dosing, and 58% (28/48) of non‐ADC drugs approved with body size‐based dosing had an α < 0.7 where fixed dosing would be appropriate. Therefore, only the remaining 16% (20/126) of non‐ADC drugs required body size‐based dosing. In addition, the FIH dosing approach had significant implications on the approved dosing approach with 68% (90/133) of drugs using the same dosing approach in FIH and approval. Lastly, of non‐ADC drugs evaluated, 56% (71/126) demonstrated a relationship between α and the approved dosing approach. When α did not explain the approved dosing approach, lack of clinically meaningful differences in exposure (49%, 27/55) was the most common justification. These findings confirm Wang et al. ’s and Zhang et al. ’s previous conclusions, continuing to support their recommendations. Based on these insights, a decision tree is proposed for selecting the appropriate dosing approach at each stage of drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pfizer Oncology, San Diego, California, USA.
ORCID-Profile: Andrew B SyBing, Huili Chen
Zitieren
APA
SyBing, A. B., Chen, H., & Wang, D. D. (2025). Re‐Evaluation of Fixed Dosing Versus Body Size‐Based Dosing Approaches for Large Molecule Therapeutics in Adults. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70015
Vancouver
SyBing AB, Chen H, Wang DD. Re‐Evaluation of Fixed Dosing Versus Body Size‐Based Dosing Approaches for Large Molecule Therapeutics in Adults. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.70015
BibTeX
@article{SyBing2025,
author = {SyBing, Andrew B and Chen, Huili and Wang, Diane D},
title = {Re‐Evaluation of Fixed Dosing Versus Body Size‐Based Dosing Approaches for Large Molecule Therapeutics in Adults},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.70015}
}
EUVIMED